FibroGen Statistics
Share Statistics
FibroGen has 100.77M shares outstanding. The number of shares has increased by 2.02% in one year.
| Shares Outstanding | 100.77M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.37% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 93.69M |
| Failed to Deliver (FTD) Shares | 1.17K |
| FTD / Avg. Volume | 0.08% |
Short Selling Information
The latest short interest is 4.32M, so 4.29% of the outstanding shares have been sold short.
| Short Interest | 4.32M |
| Short % of Shares Out | 4.29% |
| Short % of Float | 4.62% |
| Short Ratio (days to cover) | 3.27 |
Valuation Ratios
The PE ratio is -0.3 and the forward PE ratio is -0.56.
| PE Ratio | -0.3 |
| Forward PE | -0.56 |
| PS Ratio | 0.58 |
| Forward PS | 0.3 |
| PB Ratio | -0.42 |
| P/FCF Ratio | -0.27 |
| PEG Ratio | n/a |
Enterprise Valuation
FibroGen Inc. has an Enterprise Value (EV) of 143.01M.
| EV / Earnings | -0.5 |
| EV / Sales | 0.97 |
| EV / EBITDA | -0.55 |
| EV / EBIT | -0.51 |
| EV / FCF | -0.45 |
Financial Position
The company has a current ratio of 1.52, with a Debt / Equity ratio of -0.44.
| Current Ratio | 1.52 |
| Quick Ratio | 1.33 |
| Debt / Equity | -0.44 |
| Total Debt / Capitalization | -78.42 |
| Cash Flow / Debt | -3.51 |
| Interest Coverage | -18.14 |
Financial Efficiency
Return on equity (ROE) is 1.39% and return on capital (ROIC) is -3413.49%.
| Return on Equity (ROE) | 1.39% |
| Return on Assets (ROA) | -0.67% |
| Return on Capital (ROIC) | -3413.49% |
| Revenue Per Employee | 304.02K |
| Profits Per Employee | -584.84K |
| Employee Count | 486 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 0.45 |
Taxes
| Income Tax | 3.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -31.25% in the last 52 weeks. The beta is 0.73, so FibroGen 's price volatility has been higher than the market average.
| Beta | 0.73 |
| 52-Week Price Change | -31.25% |
| 50-Day Moving Average | 0.39 |
| 200-Day Moving Average | 0.79 |
| Relative Strength Index (RSI) | 78.27 |
| Average Volume (20 Days) | 1.40M |
Income Statement
In the last 12 months, FibroGen had revenue of 147.75M and earned -284.23M in profits. Earnings per share was -2.92.
| Revenue | 147.75M |
| Gross Profit | 128.90M |
| Operating Income | -281.81M |
| Net Income | -284.23M |
| EBITDA | -261.40M |
| EBIT | -281.81M |
| Earnings Per Share (EPS) | -2.92 |
Balance Sheet
The company has 113.69M in cash and 170.46M in debt, giving a net cash position of -56.77M.
| Cash & Cash Equivalents | 113.69M |
| Total Debt | 170.46M |
| Net Cash | -56.77M |
| Retained Earnings | -1.84B |
| Total Assets | 264.42M |
| Working Capital | 54.00M |
Cash Flow
In the last 12 months, operating cash flow was -315.02M and capital expenditures -2.52M, giving a free cash flow of -317.54M.
| Operating Cash Flow | -315.02M |
| Capital Expenditures | -2.52M |
| Free Cash Flow | -317.54M |
| FCF Per Share | -3.26 |
Margins
Gross margin is 8.72K%, with operating and profit margins of -19.07K% and -19.24K%.
| Gross Margin | 8.72K% |
| Operating Margin | -19.07K% |
| Pretax Margin | -19.41K% |
| Profit Margin | -19.24K% |
| EBITDA Margin | -176.92% |
| EBIT Margin | -190.74% |
| FCF Margin | -214.91% |
Dividends & Yields
FGEN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -470.97% |
| FCF Yield | -511.63% |
Analyst Forecast
Currently there are no analyst rating for FGEN.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -10.44 |
| Piotroski F-Score | 1 |